

Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010–2011 through 2013–2014



Jennifer M. Radin^{*}, Anthony W. Hawksworth, Christopher A. Myers, Michelle N. Ricketts, Erin A. Hansen, Gary T. Brice

Department of Operational Infectious Diseases, Naval Health Research Center, San Diego, CA 92106, USA

ARTICLE INFO

Article history:

Received 23 November 2015
Received in revised form 26 April 2016
Accepted 12 May 2016
Available online 8 June 2016

Keywords:

Vaccine effectiveness
Influenza
Postvaccination
Age groups

ABSTRACT

Background: Factors, such as age, comorbidities, vaccine type, herd immunity, previous influenza exposure, and antigenic shift may impact the immune response to the influenza vaccine, protection against circulating strains, and antibody waning. Evaluating vaccine effectiveness (VE) is important for informing timing of vaccine administration and evaluating overall vaccine benefit.

Methods: VE was assessed using febrile respiratory illness surveillance among Department of Defense non-active duty beneficiaries from influenza seasons 2010–2011 through 2013–2014. Respiratory specimens were taken from participants meeting the case definition and tested by polymerase chain reaction for influenza. VE was calculated using logistic regression and by taking 1 minus the odds ratio of being vaccinated in the laboratory confirmed positive influenza cases versus laboratory confirmed negative controls. **Results:** This study included 1486 participants. We found an overall adjusted VE that provided significant and fairly consistent protection ranging from 54% to 67% during 0–180 days postvaccination. This VE dropped to –11% (95% confidence interval: –102% to 39%) during 181–365 days.

Conclusions: Our study found moderate VE up to 6 months postvaccination. Since the influenza season starts at different times each year, optimal timing is difficult to predict. Consequently, early influenza vaccination may still offer the best overall protection.

© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Each year roughly 5–20% of the US population is infected with influenza, resulting in an estimated 3000–49,000 deaths [1]. The best way to prevent influenza-associated disease burden is vaccination; therefore, as of 2010, influenza vaccination has been recommended for everyone in the United States, 6 months of age and older [2]. Yearly revaccination is necessary because circulating strains and/or vaccine composition change every influenza season. Additionally, previous studies have found that influenza vaccine effectiveness (VE) declines over time since vaccination in some populations does not provide significant protection in most cases after 90–120 days [3–7]. Many factors impact VE estimates and speed of decline – including age, comorbidities, herd immunity, use of adjuvants, type of vaccine administered (live attenuated or inactivated), prior natural influenza exposure, prior influenza vaccination, antigenic drift, and study design [6,8–13].

Previous studies have assessed influenza VE declines in relatively small sample sizes or from 1 influenza season [3–6,14]. Additionally, many of these studies have been conducted outside the United States, in regions that have different vaccine composition (adjuvant vs. non-adjuvanted) [6,15], and vaccine recommendations [2,16], and may also have differences in circulating strains and in the proportion of LAIV vs. IIV and quadrivalent versus trivalent vaccine which is administered. The goal of this study is to evaluate VE over time among US Department of Defense (DoD) beneficiaries during 4 influenza seasons. Gaining a better understanding of postvaccination immunity declines is important for evaluating the benefit of the vaccine and planning the timing of vaccine administration.

2. Methods

2.1. Study participants

Participants were selected from the Naval Health Research Center's (NHRC) febrile respiratory illness surveillance of DoD non-active duty beneficiaries. The surveillance sites included Naval

^{*} Corresponding author at: Scripps Translational Science Institute, 3344 North Torrey Pines Court, Suite 300, La Jolla, CA 92037, USA.

E-mail address: radin.jennifer@scrippshealth.org (J.M. Radin).

Medical Center San Diego, California; Naval Branch Health Clinic Kearny Mesa, San Diego, California; Naval Hospital Camp Pendleton, Oceanside, California; and Captain James A. Lovell Federal Health Care Center, North Chicago, Illinois. The case definition for febrile respiratory illness is a person presenting at an outpatient health care facility with an oral temperature ≥ 38.1 °C (100.5 °F) or subjective fever, and either cough or sore throat. A convenience sample of up to 20 cases per week per site were enrolled (with sampling dependent upon study staffing hours, resulting in a near random sample) with nasal, combination nasal/throat, or nasopharyngeal swabs during influenza seasons 2010–2011 through 2013–2014. Samples were frozen and sent to NHRC for testing every 1–2 weeks along with de-identified case data. Vaccine history, including vaccine type, and date of vaccination were collected from medical records and/or recall. Cases tested positive for influenza by real-time polymerase chain reaction (qPCR), and controls tested negative for influenza. Briefly, separate qPCR assays were performed for influenza A and B using standard extraction methods and with primers provided by the Centers for Disease Control. Influenza A positive samples were further tested by CDC primers to determine subtype [influenza A (H3N2) or A(pH1N1)]. Viral culture was performed on a subset of influenza-negative samples using a rhesus monkey kidney cell line to ensure that qPCR assays remained sensitive.

This study included participants enrolled during seasonal epidemic influenza periods, which were defined as times of consistent circulation and identification of influenza positive cases. Participants with unknown influenza vaccine status or known influenza vaccine status but unknown vaccine date were excluded, as were those vaccinated <15 days or >365 days before sampling.

This research was conducted in compliance with all applicable federal and international regulations governing the protection of human subjects in research (Protocol NHRC.2007.0024). Participants gave written informed consent or parental informed consent if underage. Since all specimens in this study were collected previously and were de-identified for the purposes of this study, the NHRC institutional review board committee classified this study as minimal risk, exempt from full committee review.

2.2. Statistical analysis

Chi-squared and analysis of variance tests were used to compare the characteristics of cases and controls (Table 1). VE was calculated using logistic regression and by taking 1 minus the odds ratio (OR) of being vaccinated multiplied by 100 in the cases versus controls. The following variables were assessed in the adjusted VE model: age group (0–4 years, 5–24 years, 25–49 years, 50–64 years, and ≥ 65 years), gender, influenza season (2010–2011, 2011–2012, 2012–2013, 2013–2014), and calendar season (November–December, January–February, March–June). Confounders (>10% change in OR) or variables with $P < .05$ in the multivariate model were left in the final adjusted model. The final model adjusted for age group (0–4, 5–24, 25–49, 50–64, and >64 years), calendar season, and influenza season. Overall VE estimates were also stratified by participants who were 0–14, 15–30, 31–60, 61–90, 91–180, and 181–365 days postvaccination. Additionally, age group (0–4, 5–24, and ≥ 25 years), type of vaccine (inactivated influenza vaccine [IIV] versus live-attenuated influenza vaccine [LAIV]), influenza subtype, influenza season, and month stratifications were run for 15–90, 91–180, and 180–365 days postvaccination (Supplementary Table 1 and Figs. 1–3). SAS version 9.3 was used for all statistical analyses (SAS Institute Inc., Cary, North Carolina).

3. Results

During the 4 influenza seasons examined for our study, 1720 participants meeting the febrile respiratory illness case definition

Table 1

Descriptive characteristics among cases (influenza positive) and controls (influenza negative), excluding those <15 days or >365 days postvaccination, $n = 1481$.

Characteristic	Cases, $n = 387$ (%)	Controls, $n = 1094$ (%)	p value
Age group (years)			<0.001
0–4	72 (19)	400 (37)	
5–24	206 (53)	436 (40)	
25–49	67 (17)	161 (15)	
50–64	37 (10)	86 (8)	
>64	5 (1)	11 (1)	
Sex (% Men)	173 (45)	490 (45)	0.965
Influenza vaccine (% Yes)	91 (24)	521 (48)	<0.001
Mean \pm SD vaccination days	119 \pm 56	108 \pm 52	0.063
Influenza vaccine type (% IIV)	69 (76)	407 (79)	0.471
Influenza season			<0.001
2010–2011	76 (20)	118 (11)	
2011–2012	94 (24)	211 (19)	
2012–2013	137 (35)	294 (27)	
2013–2014	80 (21)	471 (43)	
Calendar season			0.002
November–December	83 (21)	199 (18)	
January–February	199 (51)	487 (45)	
March–June	105 (27)	408 (37)	

Abbreviations: IIV, inactivated influenza vaccine; SD, standard deviation.

were enrolled, with 198 were excluded due to incomplete vaccination history, 36 were excluded due to vaccination <15 days before diagnosis, 5 excluded due to vaccination >365 days after diagnosis. Among the remaining 1481 participants, 387 (26%) were cases (influenza qPCR positive), and 1094 (74%) were controls (influenza negative). Viral culture testing of a subset of qPCR-negative samples showed that qPCR sensitivity remained high (>99%) throughout the study. Twenty-four percent of the cases and 48% of the controls were vaccinated. Among those vaccinated, mean vaccination days were similar for cases (119 days) and controls (108 days) ($P = .063$). The percentage of participants receiving IIV vaccination was very similar in both groups, with 76% among cases and 79% among controls ($P = .471$). There were some differences in the proportion of cases versus controls across influenza seasons, likely suggesting differences in flu severity or vaccine match from season to season. The majority (53%) of the cases occurred in the 5–24 year age group. Both cases and controls had similar percentages of men and women ($P = .965$; Table 1).

Age, influenza season, and calendar season were all statistically significant in the multivariate logistic regression model. Age group was the only variable that was also a confounder. During the 0–14, 15–30, 31–60, 61–90, and 91–180-day intervals, overall VE estimates were fairly constant, with VE estimates fluctuating from 53% to 67% and remaining significant. After 180 days, overall adjusted VE estimates dropped to -16% (95% confidence interval [CI]: -117% to 38%) (Supplementary Table 1 and Fig. 1).

Stratified analyses by vaccine type, age group, and influenza subtype revealed no significant differences between adjusted VE during the 15–90 and 91–180 days postvaccination time periods, with a marked decrease in VE after 180 days. Exceptions were seen in 2 subgroups (25 years of age and older; A/pH1N1 subtype) that did not show a marked decrease in VE point estimates after 180 days, although confidence intervals were wide for these intervals (Supplementary Table 1 and Fig. 1).

Our study found slightly lower adjusted VE point estimates later in the influenza season (March, April, May) compared with early in the influenza season (December, January, February), as the ratio for percent influenza positive between unvaccinated and vaccinated groups became incrementally smaller until being nearly identical in May (Fig. 2).




Fig. 1. Adjusted^a influenza vaccine effectiveness^b estimates (95% CI) by days postvaccination, overall and stratified by influenza vaccine type, age group, and influenza subtype. Data from 2010–2011 through 2013–2014. *Abbreviations:* CI, confidence interval; IIV, inactivated influenza vaccine; LAIV, live-attenuated influenza vaccine. ^aLogistic regression model adjusted for age group (0–4 years, 5–24 years, 25–49 years, 50–64 years, >64 years), calendar season (November–December, January–February, March–June), and influenza season (2010–2011, 2011–2012, 2012–2013, 2013–2014), unless already stratified by that variable. ^bVaccine effectiveness = (1 – Odds Ratio) × 100.

When assessing VE estimates by influenza season, we found similar trends with higher protection during the 15–90 and 90–180-day periods compared with >180-day period. VE estimates during the 15–180-day period ranged from 54% to 70% and were statistically significant for all influenza seasons except 2010–2011 (Fig. 3).

4. Discussion

Comparing VE declines across studies can be difficult due to variations in vaccine group recommendations, type of vaccine used (adjuvanted versus unadjuvanted, IIV versus LAIV), herd immunity, prior vaccination, regional circulating strains, timing of the influenza season, vaccine match, and study design. Previous studies have found declines in VE for influenza A (H3N2) over time, with their VE estimates showing non-significant protection from the vaccine after several months [3–7] or evidence for increased infection with longer time since vaccination [14]. However, some of

these studies had relatively small sample sizes and thus may have been underpowered to identify statistically significant VE even when it existed. This study is the first to assess waning influenza VE over time by examining 4 seasons of influenza data and looking at multiple subtypes in the United States.

Unlike prior VE studies, our study showed significant influenza vaccine protection up to 6 months postvaccination with only slight, but not significant, declines in some stratified VE estimates. The longer protection found in our study is supported by a similar study which found that influenza hemagglutinin (HA) and neuraminidase (NA) titers declined slowly over 18 months following influenza vaccination [17]. Surprisingly, our study even found moderate VE estimates during the first 2 weeks postvaccination, which is the period during which antibodies develop and HA and NA titers increase [1].

During 181–365 days postvaccination, our study showed significant declines in protection with overall adjusted VE equal to –16% (95% CI: –117% to 38%) (Table 1 and Fig. 1). Previous studies




Fig. 2. Influenza percent positivity among vaccinated and non-vaccinated individuals and adjusted^a influenza vaccine effectiveness with 95% CI, stratified by month of illness. *Abbreviation:* CI, confidence interval. ^aLogistic regression model adjusted for age group (0–4 years, 5–24 years, 25–49 years, 50–64 years, >64 years) and influenza season (2010–2011, 2011–2012, 2012–2013, 2013–2014). ^bInfluenza vaccine effectiveness for May is equal to –66 (95% CI: –768 to 68). No vaccinated cases were identified in November or June.




Fig. 3. Adjusted^a influenza vaccine effectiveness^b estimates (95% CI) by days postvaccination, stratified by influenza season. *Abbreviation:* CI, confidence interval. ^aLogistic regression model adjusted for age group (0–4 years, 5–24 years, 25–49 years, 50–64 years, >64 years) and calendar season (November–December, January–February, March–June). ^bVaccine effectiveness = (1 – Odds Ratio) × 100. *Note:* Red dot indicates combined days post vaccination (15–180). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

assessing influenza protection beyond the season of vaccination have yielded mixed results. One study conducted in the United States found that the monovalent pH1N1 vaccine provided no pro-

tection from pH1N1 in the 2010–2011 influenza season [18]. However, another US study found similar VE estimates among those vaccinated in the previous season only compared with those vacci-

nated in the current season only [13]. Further studies may be necessary to evaluate protection ≥ 6 months postvaccination.

Our results coincide with those of other studies, which have also found lower VE point estimates later in the influenza season. Previous studies have postulated that these declines are the result of antigenic drift or waning immunity [3–6]. Although percent positivity among vaccinated individuals remained relatively constant, the overall amount of circulating influenza was lower at the end of the season, reflecting the decline in VE estimates (Fig. 2).

Our study used a laboratory qPCR confirmed positive and negative control design of febrile respiratory cases presenting at outpatient clinics. This is a common method of collecting case and control data for VE studies, and is the method used by the CDC for their annual VE estimates [19]. Certain times of year may have less influenza and more other respiratory illness, therefore resulting in a greater number of controls and skewed VE estimates [20]. To deal with this, we restricted our analysis to periods of seasonal epidemic influenza periods.

There have also been mixed results for the effect of repeated vaccination on protection from influenza infection. One study found that participants, who were vaccinated in the current influenza season but infrequently vaccinated or not vaccinated in any of the previous 5 influenza seasons, had higher VE compared with those who were routinely vaccinated [13]. However, serological studies have not provided evidence for lower protection in those receiving routine annual influenza vaccinations [21]. Although we did not have data on prior vaccination history and were not able to control for it in our models, it is possible that this variable impacted our VE estimates.

Another potential reason for differences between our results and those of previous studies is variances in vaccine type and composition. Although our study showed similar VE estimates for IIV versus LAIV, previous studies have shown that LAIV produces significantly higher vaccine efficacy among children compared with IIV [9]. Additionally, the use of adjuvant in flu vaccines may play a role in VE estimates and comparability of our study with prior ones done in Europe: during the 2011–2012 influenza season, 2 adjuvanted vaccines were licensed for use in the European Union [15] and in the Kissling study, 4 of the 16 vaccines used contained adjuvant [6]. Previous studies have shown that adjuvanted vaccines result in significantly higher vaccine effectiveness than non-adjuvanted vaccines in the elderly [10,11]. Since adjuvanted vaccines are not licensed for use in the United States, we would have expected the other European studies to have slightly higher VE estimates over time than our study; however, this was not the case.

Differences in vaccination recommendations and coverage between the United States and other countries may also explain our study's higher VE estimates. The United States recommends universal influenza vaccination of all individuals older than 6 months of age [2]; whereas other countries, such as Spain, recommend the vaccine and offer it free of cost for people older than 60 years of age and those with risk factors [3,16]. Older populations are especially vulnerable to waning immunity after vaccination as a result of immunosenescence or deterioration of the immune system with age. If the elderly and people with comorbidities are more likely to get vaccinated than those without comorbidities, they may also be more likely to have impaired immune responses, thus biasing the VE estimates. Additionally, if less people overall are vaccinated, herd immunity will likely be lower in these populations, thereby also lowering VE estimates.

Variances in natural exposure to influenza and prior antibodies may influence immune response to the influenza vaccine and VE estimates, especially in the elderly. A study of elderly individuals who were seronegative before vaccination found that they did not accumulate enough antibodies from 1 vaccine influenza dose

[12]. Another study found that low prevaccination antibody titers and greater age were associated with faster titer declines postvaccination [8]. Consequently, cohort effects might exist with certain age groups or with geographical populations having higher natural exposure or prior antibodies and therefore better protection against certain strains and improved response to the vaccine. We controlled for some of these factors by adjusting for age and influenza season in our model; however, we were not able to conduct elderly-stratified analyses due to the small sample size for this age group, as this study did not include any Veteran's Administration facilities that serve most of the retired military population.

The US Advisory Committee on Immunization Practices recommends that children who are aged 6 months through 8 years receive 2 doses of influenza vaccine [22]. However, in our study, only 27% of the children in this age range had received 2 doses of the influenza vaccine at the time of illness. Consequently, VE estimates for this age group are likely lower than if we had only included children who had completed the full vaccine course. Similarly, a high-dose influenza vaccine was recommended to individuals 65 years and older beginning in 2010–2011 and believed to improve protection in the elderly [23]. Unfortunately, we did not have data on the proportion who received the higher-dose vaccine.

Another limitation of our study is that we did not conduct a phylogenetic analysis of circulating strains to assess the degree of antigenic drift from year to year. This may be a factor which impacts declines in immunity over time. However, 1 study that performed a phylogenetic assessment of circulating strains did not find any antigenic drift at the end of the season, suggesting that the declines were a result of waning immunity [4]. Other studies have tried to assess the impact of antigenic drift by conducting a separate analysis for early and late season VE and have found lower VE in the late season, which may be reflective of antigenic drift [6]. We controlled for the potential impact of antigenic drift by adjusting for calendar season in our adjusted model.

This study gathered data from a well-established respiratory illness surveillance system. The consistency of this surveillance system allowed for robust comparisons across influenza seasons which have not been done before. When comparing influenza seasons, we found similar trends for each influenza season, with higher protection during 15–180 days postvaccination and declines after this period. We also observed lower VE estimates during the 2010–2011 season, which may correspond to antigenic drift of the pH1N1 strain during this influenza season [24] (Fig. 3).

Our results suggest that administering influenza vaccines closer to the start of the influenza season may increase VE slightly in some groups. However, we also found that the flu vaccine offered moderate and significant protection against influenza infection for the duration of the influenza season or up to 6 months postvaccination. Since the start of the flu season varies each year, it is somewhat difficult to predict the most opportune time to vaccinate each year. Consequently, early vaccine administration in the fall (before the start of the flu season) may still prevent the greatest number of influenza infections.

Financial support

This work was supported by the Armed Forces Health Surveillance Branch – Global Emerging Infections Surveillance and Response Section under proposal P0064_15_SD. Mr. Anthony Hawksworth, Ms. Michelle Ricketts, and Ms. Erin Hansen are employed by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. and are funded to do this work by the U.S. Government. Dr. Christopher Myers is a civilian, and CDR Gary Brice is a military service member. Dr. Jennifer Radin was employed by The Henry M. Jackson Foundation for the

Advancement of Military Medicine but now works for the Scripps Translational Science Institute.

Disclaimer

This work was supported by the Armed Forces Health Surveillance Branch – Global Emerging Infections Surveillance and Response Section. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government. Approved for public release; distribution is unlimited. U.S. Government Work (17 USC 105). Not copyrighted in the U.S. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2007.0024).

Conflicts of interest statement

None of the authors report any conflicts of interest.

Acknowledgments

We would like to thank Christian Hansen, Melinda Balansay, Jomelyne Lim, Daisy Cabrera, Scott Vo, Larivhie Falamiano, Elizabeth Lavelle, Gina Randazzo, Amanda Cowhick, Megan Sadakane, Holly Gallo, Patricia Michels, Chelsea Riha, Anton Hicks, Margaret Hayden, Lynda Addington, Cyril England, Keenan Faix, and Debby Taylor.

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.vaccine.2016.05.034>.

References

- Centers for Disease Control and Prevention. Seasonal influenza Q&A. Available at: <http://www.cdc.gov/flu/about/qa/disease.htm> [accessed 20 July 2015].
- Centers for Disease Control and Prevention. CDC's Advisory Committee on Immunization Practices (ACIP) recommends universal annual influenza vaccination. Available at: Available from: <http://www.cdc.gov/media/pressrel/2010/r100224.htm> [accessed 25 June 2014].
- Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. *Euro Surveill* 2013;18.
- Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011–2012 season in Spain, among population targeted for vaccination. *BMC Infect Dis* 2013;13:441.
- Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. *Euro Surveill* 2013;18.
- Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3N2) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. *Euro Surveill* 2013;18.
- Sullivan SG, Komadina N, Grant K, Jelley L, Papadakis G, Kelly H. Influenza vaccine effectiveness during the 2012 influenza season in Victoria, Australia: influences of waning immunity and vaccine match. *J Med Virol* 2014;86:1017–25.
- Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, et al. Long-term immunogenicity of influenza vaccine among the elderly: risk factors for poor immune response and persistence. *Vaccine* 2010;28:3929–35.
- Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* 2012;12:36–44.
- Spadea A, Unim B, Colamesta V, Meneghini A, D'Amici AM, Giudiceandrea B, et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. *Vaccine* 2014;32:5290–4.
- Van Buynnder PG, Konrad S, Van Buynnder JL, Brodtkin E, Krajden M, Ramler G, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. *Vaccine* 2013;31:6122–8.
- Matsushita M, Takeuchi S, Kumagai N, Uehara Y, Matsushita C, Arise K, et al. Pre-vaccination antibody titers can estimate the immune response to influenza vaccine in a rural community-dwelling elderly population. *Vaccine* 2012;30:1101–7.
- McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, et al. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. *Clin Infect Dis* 2014;59:1375–85.
- Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. *Vaccine* 2015;33:246–51.
- European Centre for Disease Prevention and Control. Influenza vaccination. Available at: http://www.ecdc.europa.eu/en/healthtopics/seasonal_influenza_vaccines/pages/influenza_vaccination.aspx [accessed 25 June 2014].
- European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe: overview of vaccination recommendations and coverage rates in the EU Member States for the 2012–13 influenza season. Available at: <http://ecdc.europa.eu/en/publications/Publications/Seasonal-influenza-vaccination-Europe-2012-13.pdf> [accessed 26 April 2016].
- Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. *J Infect Dis* 2015;212:1914–22.
- Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010–2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010–2011 influenza season. *J Infect Dis* 2013;207:1262–9.
- Cowling BJ, Feng S, Finelli L, Steffens A, Fowlkes A. Assessment of influenza vaccine effectiveness in a sentinel surveillance network 2010–13, United States. *Vaccine* 2016;34:61–6.
- Sullivan SG, Tay EL, Kelly H. Variable definitions of the influenza season and their impact on vaccine effectiveness estimates. *Vaccine* 2013;31:4280–3.
- Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. *Arch Intern Med* 1999;159:182–8.
- Centers for Disease Control and Prevention. Seasonal influenza vaccine dosage & administration. Q&A. Available at: <http://www.cdc.gov/flu/about/qa/vaxadmin.htm> [accessed 9 February 2015].
- Licensure of a high-dose inactivated influenza vaccine for persons aged > or = 65 years (fluzone high-dose) and guidance for use – United States, 2010. *MMWR morb mortal wklly rep*, vol. 59; 2010, p. 485–6.
- Faix DJ, Hawksworth AW, Myers CA, Hansen CJ, Ortiguerra RG, Halpin R, et al. Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses. *PLoS ONE* 2012;7:e34581.

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 0704-0188*

The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.

1. REPORT DATE (DD-MM-YYYY) 04-08-2015	2. REPORT TYPE Journal article	3. DATES COVERED (From - To) 2010-2014
--	--	--

4. TITLE AND SUBTITLE Influenza vaccine effectiveness: Maintained protection throughout the duration of influenza seasons 2010–2011 through 2013–2014	5a. CONTRACT NUMBER
	5b. GRANT NUMBER
	5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S) Radin, Jennifer M.; Hawksworth, Anthony W.; Myers, Christopher A.; Ricketts, Michelle N.; Hansen, Erin A.; Brice, Gary T.;	5d. PROJECT NUMBER
	5e. TASK NUMBER
	5f. WORK UNIT NUMBER 60805

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Commanding Officer Naval Health Research Center 140 Sylvester Rd San Diego, CA 92106-3521	8. PERFORMING ORGANIZATION REPORT NUMBER 16-05
---	--

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Commanding Officer Naval Medical Research Center 503 Robert Grant Ave Silver Spring, MD 20910-7500	Chief, Bureau of Medicine and Surgery (MED 00), Navy Dept 7700 Arlington Blvd Ste 5113 Falls Church, VA 22042-5113	10. SPONSOR/MONITOR'S ACRONYM(S) BUMED/NMRC
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION/AVAILABILITY STATEMENT
Approved for public release; distribution is unlimited.

13. SUPPLEMENTARY NOTES
Open access publication. Vaccine 34(33), 3907–3912, 19 July 2016, doi:10.1016/j.vaccine.2016.05.034

14. ABSTRACT
Background: Factors, such as age, comorbidities, vaccine type, herd immunity, previous influenza exposure, and antigenic shift may impact the immune response to the influenza vaccine, protection against circulating strains, and antibody waning. Evaluating vaccine effectiveness (VE) is important for informing timing of vaccine administration and evaluating overall vaccine benefit.
Methods: VE was assessed using febrile respiratory illness surveillance among Department of Defense non-active duty beneficiaries from influenza seasons 2010–2011 through 2013–2014. Respiratory specimens were taken from participants meeting the case definition and tested by polymerase chain reaction for influenza. VE was calculated using logistic regression and by taking 1 minus the odds ratio of being vaccinated in the laboratory confirmed positive influenza cases versus laboratory confirmed negative controls.
Results: This study included 1486 participants. We found an overall adjusted VE that provided significant and fairly consistent protection ranging from 54% to 67% during 0–180 days postvaccination. This VE dropped to –11% (95% confidence interval: –102% to 39%) during 181–365 days.
Conclusions: Our study found moderate VE up to 6 months postvaccination. Since the influenza season starts at different times each year, optimal timing is difficult to predict. Consequently, early influenza vaccination may still offer the best overall protection.

15. SUBJECT TERMS
vaccine effectiveness, influenza, postvaccination, age groups

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 6	19a. NAME OF RESPONSIBLE PERSON Commanding Officer
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (Include area code) COMM/DSN: (619) 553-8429